Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

作者: Muhammed Kizilgul , Tuncay Delibasi

DOI:

关键词:

摘要: The gut is similar to an endocrine organ, and produces several hormones substances with endocrine, paracrine, autocrine neurocrine effects. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are derived from cells, they can occur anywhere along the gut. In GEP-NETs, normal physiological regulations of lost, released autonomously. Although majority GEP-NETs sporadic, also be part familial syndromes such as multiple neoplasia type 1 (MEN1) syndrome, von-Hippel-Lindau disease, tuberous sclerosis neurofibromatosis 1. rare, incidence 2.5-5 cases per 100,000. Due increased availability advanced endoscopic radiological imaging, diagnosis benign incidentally identified lesions has over past decades. Except for nonfunctioning extensive release by tumor into circulation leads diverse clinical manifestations. Hormones peptides [chromogranin, neurotensin, pancreatic polypeptide (PP), or neuron-specific enolase] frequently ectopically nonfunctional but these do not cause distinct syndromes. recent years, there have been significant advances in treatment tumors. this review, features different types well aspects their medical management will discussed.

参考文章(130)
M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, C. Uprimny, P. Kovacs, E. Von Guggenberg, R. Bale, I. J. Virgolini, 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT The Journal of Nuclear Medicine. ,vol. 48, pp. 508- 518 ,(2007) , 10.2967/JNUMED.106.035667
Baback Moayedoddin, Fargol Booya, Robert A. Wermers, Ricardo V. Lloyd, Joseph Rubin, Geoffrey B. Thompson, Vahab Fatourechi, Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocrine Practice. ,vol. 12, pp. 394- 400 ,(2006) , 10.4158/EP.12.4.394
F. JOHN SERVICE, M. MOLLY McMAHON, PETER C. O'BRIEN, DAVID J. BALLARD, Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clinic proceedings. ,vol. 66, pp. 711- 719 ,(1991) , 10.1016/S0025-6196(12)62083-7
Irvin M. Modlin, Kevin D. Lye, Mark Kidd, A 5‐decade analysis of 13,715 carcinoid tumors Cancer. ,vol. 97, pp. 934- 959 ,(2003) , 10.1002/CNCR.11105
Paul A. Robiolio, Vera H. Rigolin, John S. Wilson, J. Kevin Harrison, Linda L. Sanders, Thomas M. Bashore, Jerome M. Feldman, Carcinoid Heart Disease Circulation. ,vol. 92, pp. 790- 795 ,(1995) , 10.1161/01.CIR.92.4.790
Jun Soga, Yasuko Yakuwa, Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. Journal of Hepato-biliary-pancreatic Surgery. ,vol. 5, pp. 312- 319 ,(1998) , 10.1007/S005340050052
M. Wong, S. H. Md Isa, M. Zahiah, K. Nor Azmi, Intraoperative Ultrasound with Palpation is Still Superior to Intra-arterial Calcium Stimulation Test in Localising Insulinoma World Journal of Surgery. ,vol. 31, pp. 586- 592 ,(2007) , 10.1007/S00268-006-0106-5
Homayoun Shojamanesh, Fathia Gibril, Adeline Louie, Jeremiah V. Ojeaburu, Showkat Bashir, Alaa Abou-Saif, Robert T. Jensen, Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma Cancer. ,vol. 94, pp. 331- 343 ,(2002) , 10.1002/CNCR.10195
STEVEN W. J. LAMBERTS, ERIC P. KRENNING, JEAN-CLAUDE REUBI, The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews. ,vol. 12, pp. 450- 482 ,(1991) , 10.1210/EDRV-12-4-450
Robert T. Jensen, Bruno Niederle, Emmanuel Mitry, John K. Ramage, Thomas Steinmüller, V. Lewington, Aldo Scarpa, Anders Sundin, Aurel Perren, David Gross, Juan M. O’Connor, Stanislas Pauwels, Günter Klöppel, Gastrinoma (duodenal and pancreatic) Neuroendocrinology. ,vol. 84, pp. 173- 182 ,(2006) , 10.1159/000098009